Importantly, our results from the analysis of RHOB expression in a series of samples from EGFR‐mutated lung adenocarcinoma patients treated with EGFR‐TKI showed that sensitivity to EGFR‐TKI treatment is strikingly higher in patients presenting low RHOB levels, while patients with high RHOB levels had a stronger resistance to treatment. Here, EGFR is linked to lung adenocarcinoma.